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ABSTRACT
Objectives Interleukin (IL)-23 has been implicated in
the pathogenesis of ankylosing spondylitis (AS). The aim
of the study was to clarify the mechanisms underlying
the increased IL-23 expression in the gut of AS patients.
Methods Consecutive gut biopsies from 30 HLA-B27+
AS patients, 15 Crohn’s disease (CD) patients and 10
normal subjects were obtained. Evidence for HLA-B27
misfolding was studied. Unfolded protein response (UPR)
and autophagy were assessed by RT-PCR and
immunohistochemistry. The contribution of UPR and
autophagy in the regulation of IL-23 expression was
evaluated in in vitro experiments on isolated lamina
propria mononuclear cells (LPMCs).
Results Intracellular colocalisation of SYVN1 and FHCs
but not a signiﬁcant overexpression of UPR genes was
observed in the gut of AS patients. Conversely,
upregulation of the genes involved in the autophagy
pathway was observed in the gut of AS and CD patients.
Immunohistochemistry showed an increased expression of
LC3II, ATG5 and ATG12 but not of SQSTM1 in the ileum of
AS and CD patients. LC3II was expressed among
inﬁltrating mononuclear cells and epithelial cells resembling
Paneth cells (PC) and colocalised with ATG5 in AS and CD.
Autophagy but not UPR was required to modulate the
expression of IL-23 in isolated LPMCs of AS patients with
chronic gut inﬂammation, CD patients and controls.
Conclusions Our data suggest that HLA-B27 misfolding
occurs in the gut of AS patients and is accompanied by
activation of autophagy rather than a UPR. Autophagy
appears to be associated with intestinal modulation of IL-
23 in AS.
INTRODUCTION
Subclinical ileal inﬂammation, resembling Crohn’s
disease (CD), has been demonstrated in up to 70%
of ankylosing spondylitis (AS) patients apparently
never resolving, suggesting the presence of chronic
alterations in host–microbe interactions in the
gut.1–3 The terminal ileum of normal subjects basic-
ally produces interleukin (IL)-23 in the presence of
commensal microbes4 and its local excessive pro-
duction has been found in the gut of AS patients
with subclinical gut inﬂammation,5 suggesting that
intestinal mucosa may be a key site of IL-23 pro-
duction in AS. IL-23 pathway has been
hypothesised to be strongly involved in the patho-
genesis of AS based on the cumulating genetic
evidence from several genome-wide association
study (GWAS) studies.6–8
Although increased concentrations of IL-23 have
been demonstrated in the peripheral blood9–11 and
tissues of AS patients, the exact mechanism involved
in IL-23 upregulation has not been deﬁnitively
deﬁned. In particular, it is not clear whether or not
the overproduction of IL-23 could be linked to the
misfolding of HLA-B27 through the induction of the
unfolded protein response (UPR).12 On the other
hand, the demonstration that IL-23 is active at intes-
tinal mucosal surfaces4 and evidence that certain
types of bacterial stimuli may inﬂuence its intestinal
expression13 could suggest a role for microbes in the
IL-23 overexpression observed in AS.14
A key role in the intestinal innate immune response
against bacterial infection is played by macroauto-
phagy15 (hereafter referred as autophagy), a basic cel-
lular machinery responsible in eukaryotic cells for
bulk degradation of cellular constituents16 that also
act as an effector of pattern recognition receptor
response to pathogens,17–19 directly eliminating intra-
cellular microbes or their products. Another function
of autophagy is connected to its ability to target
improperly folded proteins for degradation in close
connection with the endoplasmic reticulum stress
response known as the UPR.20–22
In this study, we present data on autophagy as a
probable regulator of IL-23 production in the gut of
patients with subclinical gut inﬂammation. We also
provide the ﬁrst evidence that HLA-B27 misfolding
occurs in the gut of HLA-B27+ AS patients.
METHODS
Patients
Multiple adjacent ileal mucosal biopsies from
patients with AS (diagnosed according to the modi-
ﬁed New York classiﬁcation criteria),23 CD and
healthy subjects were consecutively obtained (base-
line characteristics of patients and controls are speci-
ﬁed in table 1). As a control group, 10 normal
subjects undergoing to ileocolonscopy for diagnostic
purposes but without evidence of underlying
disease were also considered. Collection of ileal
biopsies was approved by the ethical committee and
Ciccia F, et al. Ann Rheum Dis 2013;0:1–9. doi:10.1136/annrheumdis-2012-202925 1
Basic and translational research
the institutional review board of the University of Palermo and
informed consent was obtained from each patient and control.
RNA extraction and quantitative TaqMan real-time
polymerase chain reaction (RT-PCR) for human epithelial cell
lines and ileal biopsies
Ileal biopsies, immediately after removal were stored in
RNAlater solution (Applied Biosystems, Foster City, California,
USA) and processed as previously described.24 For quantitative
TaqMan real-time PCR, sets of primers and probes were
obtained from Applied Biosystems (see online supplementary
table S2). Samples were run in triplicate using the Step-One
Real-Time PCR system (Applied Biosystems). Relative changes in
gene expression between controls and patients were determined
using the ΔΔCt method as previously described.
24 Final values
were expressed as fold of induction.
Histomorphological grading and immunohistochemistry
Specimens from patients with AS were divided into three
subgroups:5 those with normal gut histology, those with acute
inﬂammation and those with chronic inﬂammation.
Immunohistochemistry was performed as previously described.24
The primary and secondary antibodies used are listed in table 2. The
number of immunoreactive cells was determined by counting the
reactive cells on microphotographs obtained from three randomly
selected high-power microscopic ﬁelds (original magniﬁcation
×400). To speciﬁcally address the presence of heavy chains (HCs)–
HRD1 complexes, as a marker of misfolding,25 a double staining
was performed on parafﬁn-embedded sections of human ileum and
the sections were treated with FITC- or Rhodamine Red-conjugated
antimouse or antirabbit antibodies plus RNasi (200 ng/ml) and
counterstained using Toto-3 iodide (642/660; Invitrogen). Confocal
analysis was used to acquire ﬂuorescence staining.
Isolation of LPMCs and ﬂow cytometry analysis of surface
and intracellular antigens
Lamina propria mononuclear cells (LPMCs) were isolated from
gut biopsy specimens of 12 patients with AS and chronic gut
inﬂammation, 10 CD patients and 10 healthy controls as previ-
ously described.24 26 In order to evaluate the role of UPR and
autophagy in regulating the production of IL-23p19 by lamina
propria macrophages and dendritic cells, isolated cells were stimu-
lated with thapsigargin (1 mM, to activate UPR), 3-methyl-adenine
(100 μg/ml, to inhibit autophagy) and anisomycin (10 μg/ml, to
inhibit CAM) with or without lipopolysaccharide (LPS). All cul-
tures were set up in triplicate and cells were used for real-time
polymerase chain reaction (RT-PCR) and ﬂow-cytometric analyses.
Before intracellular staining, cells were stimulated with phorbol
myristate acetate (PMA) (1 mg/ml) plus ionomycin (0.5 mg/ml) for
4 h. After 2 h Brefeldin A (10 mg/ml; Sigma Aldrich, St Louis,
Missouri, USA) was added. After simulation, the cells were stained
with PerCP-labelled CD11c (Becton Dickinson, New Jersey, USA),
ﬁxed in 4% paraformaldehyde, permeabilised with 0.1% saponin
(Sigma Aldrich) and then stained with PE-conjugated mouse anti-
human IL-23p19 antibody (R&D systems, Minnesota, USA).
Three-colour ﬂow cytometric analysis was performed using a
FACSCalibur (Becton Dickinson) and cell death was assessed by
trypan blue exclusion. At least 50 000 cells (events) were acquired
for each sample. LPMCs were expressed as percentage of cells
within the lymphocytes gate. The acquired data were analysed
using the CellQuest software program (Becton Dickinson).
Statistical analysis
Statistical analysis of quantitative variables was performed using the
Mann–Whitney rank-sum test. Spearman’s correlation analysis was
used to quantify the expression associations between the genes of
interest. p Values less than 0.05 were considered signiﬁcant.
RESULTS
Patients
No signiﬁcant differences among Bath Ankylosing Spondylitis
Disease Activity Index score, clinical manifestations and non-
steroidal anti-inﬂammatory drugs assumption were observed in
the different subgroups of AS patients (table 1). Representative
images of the intestinal biopsies of patients with AS enrolled are
shown in online supplementary ﬁgure S1.
Table 1 Baseline characteristics of the patients and controls*
AS patients no inflammation
N=6
AS patients acute
N=9
AS patients chronic
N=15
CD patients
N=15
Controls
N=10
Age, mean (range) years 32 (22–45) 31 (20–50) 33 (20–53) 38 (18–51) 60 (35–70)
Sex, no. (%) male 5 (83) 7 (78) 13 (87) 9 (60) 7 (70)
HLA-B27, no. (%) 6 (100) 9 (100) 15 (100) 1 (6) –
Disease duration, mean (range)
months
26 (18–36) 28 (11–40) 20 (8–38) 15 (4–46) NA
CRP (mg/l), mean (range) 1 (0.5–2) 1.2 (0.5–3) 1.9 (0.5–3) 6.5 (2–13)* NA
Axial involvement, no. (%) 6 (100) 9 (100) 15 (100) 1 NA
Peripheral arthritis, no. (%) – 3 (33) 4 (27) – NA
Enthesitis/dactylitis, no. (%) 1 (16) 2 (22) 2 (13) – NA
Uveitis, no. (%) – 2 (13) – NA
Concomitant medical treatment, no. (%)
NSAIDs 3 (50) 5 (55) 9 (60) – NA
Biological agents – – – – NA
Immunosuppressants – – – – NA
BASDAI score, mean (range)† 5.45 (4.2–8) 6 (4.4–9) 6.33 (5–9) NA NA
CDAI score, mean (range)‡ – – – 234 (170–334) –
*p<0.0001.
†Scores for the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) range from 0 to 10, with higher scores indicating more severe disease.
†Scores for the CDAI range from 150 to 450, with higher scores indicating more severe disease.
AS, ankylosing spondylitis; CD, Crohn’s disease; CDAI, CD Activity Index; CRP, C reactive protein; NA, not applicable; NSAIDs, non-steroidal anti-inflammatory drugs.
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Autophagy is differentially regulated in the gut of AS
patients and CD patients
We ﬁrst studied the gene expression of proteins involved in
autophagy and assessed their correlation with the expression of
IL-23p19 gene. As shown in ﬁgure 1 a strong and signiﬁcant
upregulation of ATG16L1 (ﬁgure 1A), immunity-related GTPase
family (IRGM) (ﬁgure 1B) and MAP1LC3A (ﬁgure 1C)
together with increased IL-23p19 levels (ﬁgure 1D) was
observed in the ileum of CD patients and in the chronic
inﬂamed ileum of AS patients compared with the other AS
patients and controls. Expression levels of ATG16L1, IRGM
and MAP1LC3A were correlated with the IL-23p19 levels only
in AS patients with chronic gut inﬂammation (r2=0.78, 0.67
and 0.83, respectively, p<0.0001; data not shown) and CD
patients (r2=0.66, 0.68, 0.77, respectively, p<0.0001; data not
shown). Differently from the other autophagy genes evaluated,
ATG5 and ATG12 transcripts levels were only modestly and not
signiﬁcantly increased in the ileum of patients with CD and AS
with chronic gut inﬂammation (ﬁgure 1E,, respectively).
Interestingly, HSPA8 (ﬁgure 1G) and HSP90AA1 (ﬁgure 1H)
that are markers of chaperone-mediated autophagy (CMA) were
signiﬁcantly downregulated in the gut of all AS and CD patients
compared with controls (p<0.0001), and were inversely corre-
lated with the IL-23p19 levels in both chronically inﬂamed AS
Figure 1 Macroautophagy and chaperone-mediated autophagy in the gut of ankylosing spondylitis (AS) patients. (A–H) Relative m-RNA
quantiﬁcation of ATG16L1 (A), immunity-related GTPase family (B), MAP1LC3A (C), IL-23p19 (D), ATG5 (E), ATG12 (F), HSPA8 (G) and HSP90AA1
(H) was assessed by quantitative RT-PCR in ileal biopsy specimens obtained from 30 AS, 15 Crohn’s disease patients and 10 controls. Patients with
AS were further divided into three groups: those with normal histological ﬁndings, those with acute inﬂammation and those with chronic
inﬂammation. Data are shown as mean (SD). *p<0.0001.
Table 2 List of primers and antibodies for IHC
Primers and sequences Primary and secondary antibodies
IL-23p19 Hs00372324_m1 Rabbit anti-human HSPA5 1:100 LSBio, Seattle, WA
HSPA5 Hs00607129_gH Rabbit anti-human XBP-1 1:100 Novus Biological, Littleton, CO
PDIA4 Hs01115905_m1 Rabbit anti-human LC3II 1:100 Novus Biological, Littleton, CO
GADD34 Hs00169585_m1 Rabbit anti-human ATG5 1:500 Novus Biological, Littleton, CO
XBP-1 Hs00231936_m1 Rabbit anti-human ATG12 1:500 Novus Biological, Littleton, CO
ATF6 Hs00232586_m1 Rabbit anti-human SQSTM1 1:100 Novus Biological, Littleton, CO
PERK Hs00984006_m1 rabbit IgG control antibody ab27472 1:100 AbCam, Cambridge, UK
ATG5 Hs00169468_m1 Mouse anti-human conformational HCs W6/32 1:100 Abcam, Cambridge, UK
ATG12 Hs01047860_g1 Mouse anti-human free HCs (HC10) 1:100 Reference 24
HSPA8 Hs03044880_gH Rabbit-anti-human-SYVN-1 1:100 Novus Europe, Cambridge, UK
HSP90AA1 Hs00743767_sH Biotinylated goat anti-rabbit Ig (ab64256) 1:100 AbCam, Cambridge, UK
ATG16L1 Hs00250530_m1
IRGM Hs01013699_s1
MAP1LC3A Hs01076567_g1
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patients (r2=–0.63 and −0.58, respectively, p<0.05, data not
shown) and CD patients (r2=–0.71 and −0.64, respectively,
p<0.005, data not shown) suggesting differential level of regula-
tion of intestinal autophagy machinery.
In light of the differential expression of autophagy genes, we
evaluated the protein expression of ATG5, ATG12 and LC3 by
immunohistochemistry. A strong diffuse expression of LC3 was
found only in the parafﬁn-embedded AS ileal samples with
chronic gut inﬂammation (ﬁgure 2A–D) and CD patients (data
not shown). The classic punctate LC3 staining, characteristic of
autophagosome buildup, was clearly observed only in the frozen
ileal samples (ﬁgure 2C) among inﬁltrating mononuclear cells
and among some epithelial cells that we hypothesised to be
Paneth cells (PC) because of their pyramidal shape (ﬁgure 2A–C,
E). Despite the absence of a clear upregulation at transcript
levels, immunohistochemical analysis showed that ATG5 (ﬁgure
2F–H,L) and ATG12 proteins (ﬁgure 2M–O,Q) were strongly
upregulated only in the gut of CD and AS patients with chronic
gut inﬂammation. Accordingly, to the increased activation of
autophagy pathway, expression of SQSTM1 was observed only
in few epithelial cells in normal controls (see online supplemen-
tary ﬁgure S2A) whereas no SQSTM1 immunoreactivity was
detectable in the gut of AS patients with chronic gut inﬂamma-
tion and CD (supplementary ﬁgure 2B and C, respectively).
In order to conﬁrm that the immunoreactivity for LC3-II
observed was associated with autophagosomes, we also examined
the colocalisation of LC3 with ATG5. As shown in online supple-
mentary ﬁgure S2, a signiﬁcant colocalisation of LC3II and
ATG5 was observed in the gut of AS patients with chronic gut
inﬂammation (supplementary ﬁgure 2E–G) and CD patients
(supplementary ﬁgure 2H–L) compared with the other AS
patients (data not shown) and healthy controls (supplementary
ﬁgure 2M–O).
UPR is not upregulated in the inﬂamed ileum of AS
Since there is a close relationship between autophagy and UPR,
we also analysed the UPR response in the gut of AS patients and
controls. The expression of the heat shock 70 kDa protein 5
(HSPA5) was assessed as a marker of global UPR.27 The three
main UPR pathways were also evaluated through the measure of
the expression of PDIA4, GADD34, ATF6, protein kinase-like
endoplasmic reticulum kinase (PERK) and XBP1. The expres-
sion levels of HSPA5 (ﬁgure 3A), PDIA4 (ﬁgure 3B), GADD34
(ﬁgure 3C) and ATF6 (ﬁgure 3D) were similar in the ileal
samples from patients and controls, whereas PERK expression
was signiﬁcantly less in the gut of all AS and CD patients (ﬁgure
3E). Different regulation of XBP-1 was observed. Unspliced
XBP-1 (ﬁgure 3F) was in fact upregulated in the gut of AS
Figure 2 Autophagy is upregulated in the gut of ankylosing spondylitis (AS) patients. A 5 μm-thick parafﬁn-embedded sections of ileal biopsies
obtained from AS, Crohn’s disease (CD) patients and controls were stained with anti-LC3II, anti-ATG5 and anti-ATG12 antibodies. (A–C)
Representative microphotographs showing LC3II immunostainings in heavy chain (HC) (A), and AS patients with chronic inﬂammation (B, C).
(C) Representative immunostaining of LC3II staining on frozen samples obtained from AS patients. (E–G) Representative microphotographs showing
ATG5 immunostainings in HC (E), AS patients with chronic inﬂammation (F) and CD patients (G). (I–M) Representative microphotographs showing
ATG12 immunostainings in HC (I), AS patients with chronic inﬂammation (L) and CD patients (M). Diffuse expression of LC3II, ATG5 and ATG12 was
observed in epithelial cells and inﬁltrating mononuclear cells of AS patients with chronic gut inﬂammation and CD patients compared with controls.
Intense LC3 expression was observed in some epithelial cells of AS patients highly resembling Paneth cells (PC) for their pyramidal shape (black
arrow) (C). The classic punctate staining was highly evident among inﬁltrating mononuclear cells and PC (arrows). (A–B, D, F–I, M–P) Original
magniﬁcation ×250; (C) original magniﬁcation ×630. (D, H, N) Number of LC3+, ATG5+, ATG12+ cells in the ileal mucosa; *p<0.0001.
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patients with chronic intestinal inﬂammation and CD patients
compared with controls. Conversely, XBP-1 spliced (ﬁgure 3G)
levels were signiﬁcantly upregulated only in the gut of CD
patients, whereas XBP-1 splicing, evaluated as the ratio of
XBP1s(XBP-1s+XBP-1u),28 did not signiﬁcantly differ between
patients and controls (ﬁgure 3H). The protein levels of HSPA5
and XBP-1 were also evaluated by immunohistochemistry. As
shown in online supplementary ﬁgure S3, no signiﬁcant differ-
ential expression of HSPA5 (supplementary ﬁgure 3A–C,E) and
XBP-1 (supplementary ﬁgure F–H,L) was observed in AS and
CD patients compared with controls.
HC misfolding occurs in the gut of AS patients
The absence of a clear UPR activation prompted us to investigate
the occurrence of HC accumulation and possible misfolding. Since
SYVN1 is involved in the degradation of non-β2m bound mis-
folded major histocompatibility complex (MHC) class I HCs but
not properly conformed MHC I-β2m-peptide heterotrimers,29
double immunoﬂuorescent confocal microscopy analysis was per-
formed by using two monoclonal antibodies for HCs (the W6/32,
speciﬁc for fully assembled MHC class I molecules and the mAb
HC10, speciﬁc for β2m-free HLA-B and C HCs (FHCs), including
misfolded forms of HLA-B27) and the anti-SYVN1 antibody.
Properly folded (data not shown) and SYVN1 were both overex-
pressed in the gut of AS (ﬁgure 4A,D,E,H) and CD (ﬁgure 4I,N)
patients compared with controls (ﬁgure 4O,R). Conversely, a sig-
niﬁcantly higher amount of free HCs was detected intracellularly
only in the gut of AS patients independently by the presence/
absence of intestinal inﬂammation (ﬁgure 4B,D,F,H) and in the
HLA-B27+ CD patient (data not shown); rare colocalisation of
properly-folded HCs and SYVN1 was observed in either patients
and controls (data not shown). Interestingly, in both groups of AS
patients (independent of gut inﬂammation) (ﬁgure 4C,D,G–H)
and HLA-B27+ CD patients (data not shown) a strong colocalisa-
tion of free HCs and SYVN1 was observed, providing the ﬁrst evi-
dence of HLA-B27 misfolding in AS patients.
Autophagy but not UPR regulates IL-23p19 production
in LPMC
We next examined the contribution of UPR and autophagy to the
regulation of IL-23 expression. In this regard, isolated mono-
nuclear cells from 12 AS, 10 CD patients and 10 controls were
Figure 3 Unfolded protein response in the gut of ankylosing spondylitis (AS) and Crohn’s disease (CD) patients and healthy subjects (HS). (A–H)
Relative m-RNA quantiﬁcation of HSPA5 (A), PDIA4 (B), GADD34 (C), protein kinase-like endoplasmic reticulum kinase (D), ATF6 (E), XBP1-unspliced
(F), XBP1-spliced (G) and XBP1 ratio (H) was assessed by quantitative RT-PCR in ileal biopsy specimens from AS patients, CD patients and controls.
Data are shown as mean (SD). *p<0.0001; **p<0.05.
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analysed for the IL-23p19 expression before and after stimula-
tion with LPS, in the presence or absence of thapsigargin (TG; to
induce UPR) and 3-methyladenine (MA) (to block autophagy).
Unstimulated LPMC from AS patients with chronic gut inﬂam-
mation (ﬁgure 5A) and CD patients (ﬁgure 5C) produced signiﬁ-
cantly higher amounts of IL-23p19 compared with controls
(ﬁgure 5E). Incubation with LPS signiﬁcantly increased the
number of IL-23p19 producing LPMC from control subjects
(ﬁgure 5F) but not from AS and CD patients (ﬁgure 5B,D
respectively), suggesting a maximal preactivation of LPMC to
produce IL-23p19. Treatment and/or pretreatment of LPMC
with thapsigargin did not result in greater LPS-induced upregula-
tion of IL-23p19-producing cells in AS, CD or normal controls
(ﬁgure 5A,B), arguing against a role for UPR in the modulation
of IL-23 production in LPMC from patients and controls.
Finally, only pretreatment with the autophagy inhibitor 3-MA
and CMA-inhibitor anisomycin similarly reduced the number of
IL-23p19-expressing cells in patients and controls. Modulation
of IL-23 m-RNA levels by UPR and autophagy was also evaluated
by RT-PCR. IL-23p-19 mRNA levels in AS and CD patients were
signiﬁcantly increased only by the combination of 3-MA+LPS
and anisomycin+LPS (ﬁgure 5B,D). In healthy controls LPMCs,
LPS increased IL-23p19 expression and the preincubation with
3-MA/anisomycin further enhances this effect. Altogether these
experiments suggest that autophagy process but not the UPR acti-
vation may be involved in regulating IL-23 in the gut of AS
patients.
DISCUSSION
In this study, we conﬁrm our previous results that showed that
IL-23 is overexpressed in the gut of AS patients5 and demon-
strate for the ﬁrst time that autophagy but not the UPR is
Figure 4 Free heavy chains (HCs) and SYVN1 co-colocalise in the gut of ankylosing spondylitis (AS) patients. Immunolocalisation by confocal
microscopy of SYVN1 (green staining) and HCs (red staining) in AS, CD and control ileal biopsies. Parafﬁn-embedded section from patients and
controls were stained with rabbit antihuman SYVN-1 and mouse antihuman free HCs (HC10) antibodies and treated with FITC-conjugated antirabbit
antibody and Rhodamine Red-conjugated antimouse antibody. SYVN1 and free HCs expression was signiﬁcantly increased in the gut of AS patients
independently by the degree of intestinal inﬂammation (A, B, D and E, F, H) compared with controls (O–P, R). Signiﬁcant colocalisation of SYVN1
and free HCs was detected in the gut of AS patients independently by the degree of intestinal inﬂammation (C, D, G, H) compared with CD (M, N)
and controls (Q, R). (A–C, E–G, I–M, O–Q: original magniﬁcation ×250).
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differentially regulated and may be modulating production of
IL-23p19 in the LPMCs. Finally, we provide the ﬁrst evidence
that HLA-B27 misfolding is occurring in the gut of AS patients.
A considerable amount of genetic, immunological and thera-
peutic studies have demonstrated that IL-23 may be an import-
ant driver in AS aetiopathogenesis. The identiﬁcation of the
IL-23 pathway as a key regulator of entheseal pro-inﬂammatory
responses30 has added new arguments in favour of a patho-
physiological role of this cytokine in AS.5 9–11 Why IL-23 is
overexpressed in the gut of AS is not still known, however. The
discovery that the HLA-B27 HC is prone to misfold-inducing
endothelial reticulum (ER) stress and activating the so-called
UPR and the demonstration in a murine model that UPR activa-
tion in macrophages can promote IL-23p19 induction in
response to LPS provide a possible explanation.12 31 However,
UPR activation was not observed in human macrophages from
AS patients where IL-23 production was substantially greater
than controls 9 rendering the exact role of misfolding unclear.
MHC I HCs are retained intracellularly becoming associated
with the endoplasmic reticulum-associated protein degradation
(ERAD)-associated E3 ubiquitin-protein ligase (SYVN1) and tar-
geted for ERAD.29 In the absence of SYVN1, misfolded
HLA-B27 accumulates in the cells.29 Thus, the co-colocalisation
of SYVN1 together with non-β2m bound (HC-10-reactive)
MHC class I HCs discriminates misfolded MHC class I from
properly folded MHC I-β2m-peptide heterotrimers.29 In our
study, in the chronically inﬂamed gut of AS, both conform-
ational and free HCs were overexpressed but only the unbound
HCs signiﬁcantly colocalised with SYVN1, strongly suggesting
the occurrence of HLA-B27 misfolding in the intestine of
HLA-B27+ AS patients.
IL-23 is constitutively produced in the terminal ileum in the
presence of commensal microbes and plays an important role in
the host defence against bacterial infection.4 Subclinical gut
inﬂammation has been demonstrated in a considerable percent-
age of AS patients and it seems to be immunologically
Figure 5 Autophagy but not unfolded protein response (UPR) regulates the production of IL-23 in lamina propria mononuclear cells (LPMCs).
LPMCs isolated from patients with ankylosing spondylitis (AS), Crohn’s disease (CD) and heavy chains (HCs) were cultured in the presence of
lipopolysaccharide (LPS), 3-MA/anisomycin (to block autophagy) and TG (to induce UPR) alone and with LPS+TG and LPS+3-MA. The percentage of
IL-23-producing cells and the m-RNA levels of IL-23p19 were evaluated by ﬂow cytometry and RT-PCR, respectively. The percentage of IL-23
producing cells and the m-RNA levels were modiﬁed in AS (A) and CD (C) only by the combination of 3MA/anisomycin and LPS. In normal controls
(E), LPS alone increased the percentage of IL-23-producing cells and the levels of IL-23 that were not further increased by the co-incubation with
TG. Blocking of autophagy and chaperone-mediated autophagy signiﬁcantly reduced the number of IL-23-producing cells in AS and CD and
restrained the LPS-dependent IL-23 expression in LPMC from controls, also increasing the IL-23p19 m-RNA levels (B, D, F). *p<0.05. (G)
Representative dot plot of CD45 versus CD11c+ cells among LPMC from AS patients. (H, I) Representative dot plot showing the percentage of IL-23
expressing cells before (H) and after (I) 3-MA/LPS incubation.
Ciccia F, et al. Ann Rheum Dis 2013;0:1–9. doi:10.1136/annrheumdis-2012-202925 7
Basic and translational research
characterised by the increased expression of IL-235 perhaps as
the result of chronic alterations in host–microbe interactions. In
the gut of AS patients, the main source of IL-23 is represented
by inﬁltrating inﬂammatory mononuclear cells and PC,5 a subset
of specialised epithelial cells that is considered to have a role in
innate immune function through the secretion of antimicrobial
peptides.23 This secretory function seems to be closely related
to the autophagy pathway, as suggested by the PC granule
abnormalities observed in CD patients who have polymorphisms
in the autophagy gene Atg16L1.32
Autophagy is a mechanism of controlled digestion of
damaged organelles within a cell that may be differentiated in
macroautophagy, in which entire regions of cytosol are seques-
tered in vesicular compartments and CMA that is exclusively
dedicated to degradation of soluble proteins.33 During infection,
autophagy may be also induced as an innate defence mechanism
to eliminate bacteria or toxins20 21 and activation of autophagy
has been demonstrated in PC of patients with CD independently
of disease-associated variants of ATG16L1 or IRGM.34
In our study in the inﬂamed gut of AS and CD patients, a dif-
ferent regulation of autophagy and CMA was observed. The
expression of macroautophagy genes was in fact signiﬁcantly
upregulated in comparison with healthy subjects whereas CMA
appears to be importantly downregulated. The macroautophagy
activation was conﬁrmed by the immunohistochemistry experi-
ments as recommended by the recently published guidelines for
the use and interpretation of assays for monitoring autophagy.35
LC3II, a marker of global autophagy, was demonstrated to be in
fact upregulated in the gut of AS and CD patients and associated
with autophagosome formation, as suggested by the strong colo-
calisation of with ATG5. Two additional markers of autophagy,
ATG5 and ATG12, were also found to be increased at protein
level in the gut of AS and CD patients. Finally, SQSTM1, a ubi-
quitin binding protein that accumulates when autophagy is
inhibited, and is reduced when autophagy is induced, was not
detectable in the gut of CD patients and AS patients with
chronic gut inﬂammation.
Interestingly, increased autophagy gene expression was corre-
lated with augmented IL-23p19 levels. In this regard, numerous
cytokines have been shown to regulate autophagy in macrophages
and dendritic cells and, obviously, we cannot exclude that the
increased autophagy expression in the AS gut may be the conse-
quence rather than the cause of IL-23 overexpression. Since the
important role of PC in the defence against microorganisms and
their activation is to release antimicrobial peptides in both AS and
CD ileal samples,36 we can also speculate that speciﬁc microbiota
alterations could drive activation of autophagy in CD and AS.
However, our data suggest that autophagy may be one of the
immunological factors regulating the production and secretion of
IL-23 in AS. Speciﬁcally, inhibition of autophagy and CMA (with
3-MA and anisomycin) was sufﬁcient, in the presence of LPS, to
reduce the percentage of IL-23 expressing cells at the same time
increasing the mRNA levels for IL-23p19 in the LPMCs isolated
from the gut of patients and controls. The increased expression
of IL-23p19 mRNA after LPS/3-MA and LPS/anisomycin stimuli
could suggest that the reduced percentage of IL-23-producing
cells observed in ﬂow-cytometry may be attributable to the active
cellular release of IL-23. However, the signiﬁcant downregula-
tion of CMA observed in inﬂamed gut and its negative correl-
ation with IL-23 levels could suggest a role of speciﬁc branch of
autophagy pathway in modulating IL-23 response. Nevertheless,
the in vitro activation of LPMCs with PMA/ionomycin before
the incubation with 3-MA is an experimental artiﬁce that could
limit the strength of our results. In agreement with this result is
however the recent demonstration that autophagy regulates
IL-23 secretion in dendritic cells37 and our immunohistochemical
observation that autophagy is localised to the two main cellular
sources of IL-23 in the gut of AS, the inﬁltrating inﬂammatory
mononuclear cells and in those that we consider to be PC.
Our study aimed also to investigate the UPR activation in the
gut of AS patients. Similar to a previous study in macrophages,9
other than increased total (unspliced) XBP1 mRNA, we found
no evidence for UPR activation playing a role in IL-23 produc-
tion. UPR signalling is initiated by the activation of at least three
distinct stress sensors located at the ER membrane known as the
ER-resident transmembrane protein kinase-endoribonucleases
(RNase) (ERN1/IRE1α), the protein kinase PERK EIF2AK3/
PERK and a family of type II transmembrane transcription
factors, whose most prominent member is ATF6α. When
unfolded proteins accumulate in the ER, eukaryotic cells can
upregulate the expressions of the chaperone protein HSPA5
(which is used as a marker of global UPR).38 Activation of the
IRE1 kinase activity was assayed indirectly in our study by meas-
uring the levels of unspliced and spliced XBP1 mRNA (XBP1u
and XBPs, respectively), the latter of which is generated by
removal of a 26-nucleotides and results in the generation of a
functional protein (sXBP1). Activation of the PERK and ATF6
branches were evaluated by assessing the expression levels of
transcriptionally activated target genes, GADD34 and PDIA4,
respectively. No increased expression levels of UPR genes was
observed in the ileal mucosa of AS and CD patients compared
with healthy controls. Since our results support the presence of
HLA-B27 misfolding, we cannot obviously exclude that low
levels of ER stress caused by HLA-B27 in the gut of AS patients
contribute to the intense activation of autophagy, which in turn
may further limit the full UPR activation by enhancing the
removal of misfolded protein. Consistent with this concept, ER
stress has been shown to activate autophagy through PERK39
and/or XBP1.40 Interestingly, misfolded monomeric proteins
have been demonstrated to be degraded by CMA41 42 and the
downregulation of CMA could account, at least in part, for the
accumulation of misfolded proteins observed in AS gut.
In conclusion, we provide evidence that autophagy, rather
than robust UPR activation, may be an important regulator of
IL-23 production in the gut of AS patients. Since autophagy
plays an important role in the intestinal immune response
against microorganisms, our results could suggest a fundamental
role of AS intestinal microbiota in regulating intestinal IL-23
expression. We also provide the ﬁrst evidence that HLA-B27
misfolding occurs in the gut of AS. Further studies are required
to better study the speciﬁc role of autophagy and CMA in regu-
lating the immunology of the gut of AS patients.
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